MD Notes

creation date: 2026-08-19 23:59
tags: Pathologies

Idiopathic Intracranial Hypertension

Background

Definitions

Idiopathic intracranial hypertension (IIH), also referred to as pseudotumour cerebri, is a condition relating to increased intracranial pressure with no other evident causes of intracranial hypertension.

Historically, the term benign intracranial hypertension was used to distinguish it from secondary intracranial hypertension due to malignancy, but as it is not a benign disorder, has been renamed.

Pathogenesis

The precise pathogenesis is unknown. Current theories suggest that regardless of the pathway (eg. venous outflow abnormalities, increased CSF outflow resistance, obesity, related increased abdominal and intracranial venous pressure, and altered sodium/water retension mechanisms), a final common pathway exists.

In such case, the postulated result is elevated intracranial venous pressure, causing intracranial pressure to increase and thus the manifestations.

Risk Factors

Incidence: 1-2 per 100,000

IIH primarily affects females of childbearing age who are overweight.

  • Recent weight gain
  • Abrupt cessation of GLP-1
  • Family history of IIH

Some medications and systemic diseases have been reported to be associated but the evidence have been unclear. Some evidence have been found relating the following to IIH:

  • Growth hormone (dose-related manner)
  • Tetracyclines (note: evidence had confounders)
  • Hypervitaminosis A from excessive dietary intake and possibly other retinoids

Clinical Presentation

Signs & Symptoms

IIH is characterized by increased ICP, normal CSF composition, and no other intracranial hypertension cause.

  • Headache (85%)
  • Transient visual obscurations (70%)
  • Intracranial noises (eg. pulsatile tinnitus; 55%)
  • Photopsia (50%)
  • Back pain (53%)
  • Retrobulbar pain (44%)
  • Diplopia (30%)
  • Sustained visual loss (30%)
  • Neck pain (41%)

The characteristics of the headaches are not specific but patients may note:

  • Unusual severity of pain
  • Lateralized and throbbing/pulsatile
  • Occurring dailyt or less frequently
  • Associated nausea and vomiting
  • Exacerbated by changes in posture
  • Relief with NSAIDs and/or rest

History & Physical Exam

The typical presentation is:

  • Overweight female of childbearing age
  • Complaint of headaches
  • Papilledema on funduscopic exam

Physical exam should include visual field and extraocular movements (CN6 palsy). Additionally, systemic blood pressure for other causes of optic disc edema.

Diagnosis

Criteria

Diagnosis is made according to the modified Dandy criteria:

  • Symptoms and signs of increased ICP
  • No other neurologic abnormalities or impaired level of consciousness
  • Elevated intracranial pressure with normal CSF composition
  • Neuroimaging with no evidence of other etiology of intracranial hypertension
  • No other cause of intracranial hypertension apparent

Work-up

In any patient with headache in papilledema, a workup is warranted.

  • Urgent neuroimaging (exclude secondary causes of intracranial hypertension)
  • Lumbar puncture (opening pressure and CSF analysis)
  • Ophthalmologic evaluation for severity of optic nerve involvement

Differential

Other causes of papilledema (/increased intracranial pressure) include:

  • Secondary intracranial hypertension (excluded via MRI)
    • Intracranial mass lesions
      • Tumours
      • Abscess
    • Obstruction of venous outflow
      • Venous sinus thrombosis
      • Jugular vein compression
      • Neck surgery
    • Obstructive hydrocephalus
    • Decreased CSF absorption
      • Arachnoid granulation adhesions after infectious meningitis
      • Subarachnoid hemorrhage
    • Increased CSF production
      • Choroid plexus papilloma
  • Optic disc abnormalities (mimics of papilledema)

Red Flags / Complications

IIH can lead to significant loss of quality of life. Additionally, there is risk of permanent vision loss.

Management

The goals of treatment are to alleviate symptoms (typically headache) and preserve vision.

Initial Treatment

Treatment starts with addressing risk factors and comorbid conditions:

  • Weight loss
  • Sleep apnea
  • Discontinuation of medications that may contribute

Patients at risk for vision loss are those with:

  • Severe papilledema (Frisen grade 3-5)
  • Vision loss or visual symptoms

For such patients, carbonic anhydrase inhibitor acetazolamide is recommended as first line.

Monitoring and Follow Up

Patients require regular ophthalmology follow-up until stabilization. Generally will be at least monthly but depends on ophthalmologic assessment.

Intervention for Severe Disease

For patients that fail, are intolerant to, or noncompliant with medical therapy, surgical intervention may be indicated.

  • Optic nerve sheath fenestration (allows for CSF to egress into orbit and stabilize)
  • CSF shunting (ventriculoperitoneal shunt or lumboperitoneal shunt)

References

Tools / Guidelines

Additional Reading